Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - vinorelbine tartrate 13,85 mg/ml - eq. vinorelbine 10 mg/ml - concentrate for solution for infusion - 10 mg/ml - vinorelbine tartrate 13.85 mg/ml - vinorelbine

Namibia - English - Namibia Medicines Regulatory Council

cipla medpro (pty) ltd - vinorelbine tartrate - intravenous injection - each 1 ml solution contains vinorelbine tartrate equivalent to vinorelbine base 10,0 mg

Namibia - English - Namibia Medicines Regulatory Council

cipla-medpro (pty) ltd - vinorelbine tartrate - injection - each 5,0 ml solution contains vinorelbine tartrate equivalent to vinorelbine 50,0 mg

Canada - English - Health Canada

fresenius kabi canada ltd - vinorelbine (vinorelbine tartrate) - solution - 10mg - vinorelbine (vinorelbine tartrate) 10mg - antineoplastic agents

Canada - English - Health Canada

generic medical partners inc - vinorelbine (vinorelbine tartrate) - solution - 10mg - vinorelbine (vinorelbine tartrate) 10mg - antineoplastic agents

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - vinorelbine tartrate 13.85mg equivalent to to 10 mg vinorelbine - concentrate for injection - 10 mg/ml - active: vinorelbine tartrate 13.85mg equivalent to to 10 mg vinorelbine excipient: nitrogen water for injection - dbl™ vinorelbine injection concentrate is indicated as a single agent or in combination for 1. the treatment of non small cell lung cancer (nsclc), and 2. the second line treatment of advanced breast cancer.

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

eurolab (pty) ltd, south africa - vinorelbine tartrate equivalent to vinorelbine 20mg - capsules - 30

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - vinorelbine tartrate - concentrate for soln for inf - 10 mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

luminarie pty ltd - vinorelbine tartrate, quantity: 41.55 mg (equivalent: vinorelbine, qty 30 mg) - capsule, soft - excipient ingredients: gelatin; partially dehydrated liquid sorbitol; polysorbate 80; macrogol 400; titanium dioxide; purified water; iron oxide red - non-small cell lung cancer: velabine is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination. ,breast cancer: velabine is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

luminarie pty ltd - vinorelbine tartrate, quantity: 27.7 mg (equivalent: vinorelbine, qty 20 mg) - capsule, soft - excipient ingredients: purified water; polysorbate 80; iron oxide yellow; gelatin; titanium dioxide; macrogol 400; partially dehydrated liquid sorbitol - non-small cell lung cancer: velabine is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination. ,breast cancer: velabine is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.